BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2010 related articles for article (PubMed ID: 27943261)

  • 21. BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: an open, randomised, parallel-group Phase II/III trial.
    Butler K; Inshaw J; Ford D; Bernays S; Scott K; Kenny J; Klein N; Turkova A; Harper L; Nastouli E; Paparini S; Choudhury R; Rhodes T; Babiker A; Gibb D
    Health Technol Assess; 2016 Jun; 20(49):1-108. PubMed ID: 27377073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review.
    Rutherford GW; Horvath H
    PLoS One; 2016; 11(10):e0162775. PubMed ID: 27736859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
    Lapphra K; Vanprapar N; Chearskul S; Phongsamart W; Chearskul P; Prasitsuebsai W; Chokephaibulkit K
    Int J Infect Dis; 2008 Nov; 12(6):e33-8. PubMed ID: 18573672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis.
    Shubber Z; Calmy A; Andrieux-Meyer I; Vitoria M; Renaud-Théry F; Shaffer N; Hargreaves S; Mills EJ; Ford N
    AIDS; 2013 Jun; 27(9):1403-12. PubMed ID: 23343913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rate of viral load change and adherence of HIV adult patients treated with Efavirenz or Nevirapine antiretroviral regimens at 24 and 48 weeks in Yaoundé, Cameroon: a longitudinal cohort study.
    Chendi BH; Okomo Assoumou MC; Jacobs GB; Yekwa EL; Lyonga E; Mesembe M; Eyoh A; Ikomey GM
    BMC Infect Dis; 2019 Feb; 19(1):194. PubMed ID: 30808298
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings.
    Chang LW; Harris J; Humphreys E
    Cochrane Database Syst Rev; 2010 Apr; (4):CD008494. PubMed ID: 20393969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparing the effectiveness of efavirenz and nevirapine for first-line antiretroviral therapy in a South African multicentre cohort.
    Bock P; Fatti G; Grimwood A
    Int Health; 2013 Jun; 5(2):132-8. PubMed ID: 24030113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term efficacy and tolerance of efavirenz- and nevirapine-containing regimens in adult HIV type 1 Senegalese patients.
    de Beaudrap P; Etard JF; Guèye FN; Guèye M; Landman R; Girard PM; Sow PS; Ndoye I; Delaporte E;
    AIDS Res Hum Retroviruses; 2008 Jun; 24(6):753-60. PubMed ID: 18507521
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy.
    Humphreys EH; Hernandez LB; Rutherford GW
    Cochrane Database Syst Rev; 2007 Oct; (4):CD006517. PubMed ID: 17943914
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan.
    Wu PY; Cheng CY; Liu CE; Lee YC; Yang CJ; Tsai MS; Cheng SH; Lin SP; Lin DY; Wang NC; Lee YC; Sun HY; Tang HJ; Hung CC
    PLoS One; 2017; 12(2):e0171596. PubMed ID: 28222098
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
    Bannister WP; Ruiz L; Cozzi-Lepri A; Mocroft A; Kirk O; Staszewski S; Loveday C; Karlsson A; Monforte Ad; Clotet B; Lundgren JD;
    AIDS; 2008 Jan; 22(3):367-76. PubMed ID: 18195563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antidepressants for depression in adults with HIV infection.
    Eshun-Wilson I; Siegfried N; Akena DH; Stein DJ; Obuku EA; Joska JA
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD008525. PubMed ID: 29355886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Choice of initial antiretroviral drugs and treatment outcomes among HIV-infected patients in sub-Saharan Africa: systematic review and meta-analysis of observational studies.
    Ayele TA; Worku A; Kebede Y; Alemu K; Kasim A; Shkedy Z
    Syst Rev; 2017 Aug; 6(1):173. PubMed ID: 28841912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin-2 as an adjunct to antiretroviral therapy for HIV-positive adults.
    Onwumeh J; Okwundu CI; Kredo T
    Cochrane Database Syst Rev; 2017 May; 5(5):CD009818. PubMed ID: 28542796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy.
    Humphreys EH; Chang LW; Harris J
    Cochrane Database Syst Rev; 2010 Jun; (6):CD006517. PubMed ID: 20556768
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
    Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
    BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults.
    Siegfried N; Uthman OA; Rutherford GW
    Cochrane Database Syst Rev; 2010 Mar; 2010(3):CD008272. PubMed ID: 20238364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial.
    Swaminathan S; Padmapriyadarsini C; Venkatesan P; Narendran G; Ramesh Kumar S; Iliayas S; Menon PA; Selvaraju S; Pooranagangadevi NP; Bhavani PK; Ponnuraja C; Dilip M; Ramachandran R
    Clin Infect Dis; 2011 Oct; 53(7):716-24. PubMed ID: 21890776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term effectiveness of first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in Ghana.
    Sarfo FS; Sarfo MA; Kasim A; Phillips R; Booth M; Chadwick D
    J Antimicrob Chemother; 2014 Jan; 69(1):254-61. PubMed ID: 24003181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antihelminthics in helminth-endemic areas: effects on HIV disease progression.
    Means AR; Burns P; Sinclair D; Walson JL
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD006419. PubMed ID: 27075622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 101.